All In Biotech

Drug Trial Radar · NCT03573297

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 901 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

901

Actual

Start

Jun 15, 2018

Primary completion

Sep 5, 2022

Study completion Sep 5, 2022

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1\) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/day

Conditions

  • Bipolar I Disorder
  • Mania
  • Depression

Interventions

  • CariprazineDrug

    Cariprazine capsules, oral administration, once daily

  • PlaceboDrug

    Matching placebo capsules, oral administration, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Relapse of Any Mood Episode During the Double-Blind Treatment PeriodTime frame: From Week 16 to Week 55

Locations

108 sites in 11 countries. Site status is shown where the registry gives one.

  • Woodland International Research Group /ID# 232932

    Little Rock, Arkansas

  • Woodland Research Northwest, LLC /ID# 232982

    Rogers, Arkansas

  • California Pharmaceutical Research Institute Inc. /ID# 232745

    Anaheim, California

  • Advanced Research Center /ID# 233120

    Anaheim, California

  • CI Trials /ID# 232642

    Bellflower, California

  • Synexus Clinical Research US Inc. /ID# 232743

    Cerritos, California

  • ATP Clinical Research, Inc /ID# 232979

    Costa Mesa, California

  • ProScience Research Group /ID# 232945

    Culver City, California

  • Collaborative Neuroscience Research - Orange County /ID# 233077

    Garden Grove, California

  • Behavioral Research Specialists, LLC /ID# 232980

    Glendale, California

  • Omega Clinical Trials LLC /ID# 233150

    La Habra, California

  • Synergy San Diego /ID# 232740

    Lemon Grove, California

  • Alliance for Research - Long Beach /ID# 232926

    Long Beach, California

  • NRC Research Institute /ID# 232741

    Orange, California

  • CNRI-San Diego /ID# 232748

    San Diego, California

  • Artemis Institute for Clinical Research /ID# 233151

    San Marcos, California

  • Artemis Institute for Clinical Research /ID# 233152

    San Marcos, California

  • Collaborative Neuroscience Research LLC /ID# 232750

    Torrance, California

  • Duplicate_MCB Clinical Research Centers LLC /ID# 232838

    Colorado Springs, Colorado

  • Velocity Clinical Research - Hallandale Beach /ID# 232647

    Hallandale, Florida

  • Research Centers of America - Hollywood FL /ID# 232649

    Hollywood, Florida

  • CNS Healthcare - Jacksonville /ID# 233160

    Jacksonville, Florida

  • Meridien Research /ID# 232941

    Maitland, Florida

  • Miami Lakes Medical Research /ID# 232826

    Miami Lakes, Florida

  • University of South Florida /ID# 233093

    Tampa, Florida

  • Synexus Clinical Research, Inc /ID# 232950

    Atlanta, Georgia

  • Atlanta Center for Medical Research /ID# 232832

    Atlanta, Georgia

  • CenExcel iResearch LLC /ID# 233045

    Decatur, Georgia

  • Atlanta Behavioral Research, LLC /ID# 232935

    Dunwoody, Georgia

  • NeuroPsychiatric Research Practice & Associate LTD /ID# 232840

    Winfield, Illinois

  • Louisiana Clinical Research /ID# 232685

    Shreveport, Louisiana

  • CBH Health LLC /ID# 232699

    Gaithersburg, Maryland

  • St. Charles Psychiatric Associates - Midwest Research Group /ID# 232709

    Saint Charles, Missouri

  • Duplicate_Altea Research Institute /ID# 232784

    Las Vegas, Nevada

  • Hassman Research Institute /ID# 233088

    Berlin, New Jersey

  • Neurobehavioral Research Inc /ID# 232791

    Cedarhurst, New York

  • New Hope Clinical Research Inc. /ID# 232716

    Charlotte, North Carolina

  • Richard Weisler MD, PA & Assoc /ID# 233049

    Raleigh, North Carolina

  • Clinical Inquest Center Ltd /ID# 233043

    Beavercreek, Ohio

  • DUPLICATE_The Ohios State University Department of Psychiatry /ID# 232739

    Columbus, Ohio

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.